Shing I Yen, MD | |
2320 High St, Retired 12-31-2014, Blue Island, IL 60406-2426 | |
(708) 388-5500 | |
Not Available |
Full Name | Shing I Yen |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | 2320 High St, Blue Island, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093779373 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 036046660 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Shing I Yen, MD 2320 High St, Blue Island, IL 60406-2426 Ph: (708) 388-5500 | Shing I Yen, MD 2320 High St, Retired 12-31-2014, Blue Island, IL 60406-2426 Ph: (708) 388-5500 |
News Archive
Results of an Australian study published in The Journal of Pain showed that after controlling for depression internalized stigma is negatively associated with lower levels of self-esteem and personal control of pain.
The Wall Street Journal examines upcoming changes to the global strategy to eradicate polio with a focus on the Bill & Melinda Gates Foundation's role in fighting the disease. "[O]rganizations behind the polio fight," which include the WHO, UNICEF, Rotary International and the CDC, "plan to announce a major revamp of their strategy to address shortcomings exposed by" the increasing number of polio outbreaks in "countries believed to have stopped the disease." The plan is expected to be announced next week.
Psoriasis expert and researcher Steve Feldman, M.D., says there are many new treatment options giving hope to the millions of people who suffer from the chronic skin condition.
Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.
› Verified 1 days ago